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Antimicrobial resistance is a global public health challenge, which has 
accelerated by the overuse of antibiotics worldwide. Increased anti-
microbial resistance is causing severe infections, complications, longer 
hospital stays and increased mortality. Steps must be taken to reverse 
the damage that has already been done and prevent further resistance 
from developing. This review study will examine the context of anti-
microbial resistance in general with emphasis on its presence in Mo-
rocco. Second, the social situation that led to antibiotic overuse and 
misuse seen in both health care professionals and the public will be 
discussed. Third, offer solutions that have been suggested to prevent 
and reverse this problem.
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Introduction
The rapid emergence of resistant bacteria is occurring worldwide in-
cluding in Morocco and its neighboring countries endangering the 
efficacy of antibiotics, which have transformed medicine and saved 
millions of lives [1, 2]. The antibiotic resistance crisis has been attribu-
ted to the overuse and misuse of these medications. In addition, the 
lack of new drug development by the pharmaceutical industry due to 
reduced economic incentives and challenging regulatory requirements 
is a serious problem [3, 4].
Many physicians and other health care professionals prescribe an-
tibiotics with little concern of its overuse. It has become practice to 
prescribe antibiotics for common and minor sore throat, which often 
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caused by viruses and would be normally eliminated 
by a healthy immune system. Antibiotic overuse is 
leading factor to drug resistance in bacteria, and 
will ultimately result in losing most of the currently 
available antimicrobial medications [5, 6].
The aim of this study is to present data on an-
tibiotic resistance in Morocco and propose several 
solutions to this growing issue.
Brief history of antibiotic resistance
Penicillin, the first antibiotic discovered by Alexander 
Fleming in 1928 by fortunate accident was believed 
to be a miracle drug, saving the lives of thousands 
of soldiers in World War II and improving the quality 
of life for the public. However, shortly thereafter, 
penicillin resistance became a substantial clinical 
problem [7]. In response, new beta-lactam antibio-
tics were discovered, developed and deployed for 
medical use. The first case of methicillin-resistant 
Staphylococcus aureus (MRSA) was identified in the 
United Kingdom in 1962. Vancomycin was used in 
1972 for the treatment of methicillin-resistance in 
both S. aureus and coagulase-negative staphylo-
cocci. In 1979, first case of vancomycin resistance 
were reported in coagulase-negative staphylococci. 
Antibiotic development continued and increased 
throughout the following decades where numerous 
new antibiotics are becoming available for medical 
use; including carbapenems, cephalosporins, tetra-
cyclines, aminoglycosides, monobactam, macroli-
des, streptogramins [1, 8]. 
The plethora of antibiotics now available are wi-
dely and readily prescribed by medical providers for 
human and animal. All are being used in an alar-
mingly pattern that is fueling and contributing to 
the current antibiotic resistance problem. In short, 
this crisis is a result of many factors; pharmaceutical 
companies practice in offering incentives for physi-
cians, lack of solid knowledge about antibiotics of 
prescribers and antibiotic resistance pattern in their 
society, patients negligees, misuse and overuse in 
agriculture and animal husbandry, and the genetic 
abilities of many bacteria species to develop rapidly 
resistance to certain antibiotics [8, 9].
Context Leading to Antibiotic 
Resistance
Role of pharmaceutical industry
Pharmaceutical companies discover, develop, and 
market new antibacterials. Clearly, it is in the best 
interests of pharmaceutical companies to promote 
wide use of antibacterials in order to justify research 
and development costs. Big pharmaceutical compa-
nies obtained huge profits and ensured the com-
panies' commitment to develop and market many 
new antibiotics for medicine. This fact, coupled with 
the willingness of some physicians to prescribe the 
latest antibacterial, has undoubtedly increased the 
frequency of resistance over time. Between 1988 
and 2000, many new antibiotics were available and 
profitable during these years [11]. 
Animal testing laws in particular were in the past 
much easier to carry out testing [12]. Since 2003, 
only one new antibiotic per year on average has 
been approved by the FDA for medical treatment 
[11]. The largest names in pharmaceuticals, including 
Wyeth, Eli Lilly, Procter and Gamble, Roche, Abbott 
Laboratories, and Aventis have either largely redu-
ced their antibiotic research and development or 
terminated their antibiotic research entirely [10-11]. 
It is simply not as profitable to focus on antibiotics 
as other areas of drug research. These companies 
have shifted their research and development focus 
to medications with wider markets and higher pro-
fit margins. Drugs that are used in the treatment 
of chronic diseases are of particular interest to big 
pharmaceutical companies. Antibiotics are much 
more difficult and expensive to manufacture than 
medications for conditions such as diabetes, high 
cholesterol, depression and arthritis. Antibiotics are 
far less profitable than other so called “maintenance 
medications”. Antibiotics are only used for a short 
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duration and will only be utilized periodically during 
a person’s lifetime. It is understandably difficult to 
make any profit on the development of a medica-
tion that will only be used for approximately ten 
days at a time every other year, especially when 
antibiotics are so difficult to develop and test for 
human use. There is a lot more money to be made 
from so called “blockbuster” drugs than from anti-
biotics that will only be used periodically and for a 
short duration by patients [11]. 
A study published by Huttner et al. [13] found 
that pharmaceutical companies spent roughly 1.6 
billion dollars in 1998 to promote antibiotics to cus-
tomers, hospitals, doctor’s offices, and pharmacies. 
This investment could easily be spent in the pursuit 
of new antibiotics or on safe antibiotic usage cam-
paigns. Sadly, it is being used only to market and 
encourage the further use of already well-establis-
hed antibiotics.
Role of medical doctors
Physician’s decisions with regard to prescriptions 
are very complex and determined by many factors. 
Clearly, in cases of infectious disease, the decision 
to treat is based on the diagnosis of bacterial in-
fection or on the likelihood of a bacterial infection. 
The dose and type of antibacterial are chosen on 
the basis of the likely pathogen and its local in vitro 
susceptibility, the severity of the infection, and the 
condition of the patient. In most situations, neither 
the pathogen nor its in vitro susceptibility is known. 
Antibiotic use is increasing substantially worldwide, 
though it is increasing to the largest degree in the 
United States and other highly developed countries 
[1-2, 5]. Antibiotic over-prescription is understood to 
be very expensive and known to contribute to the 
growing resistance of bacteria [6-8]. 
Antibiotics are being vastly overused and misused 
and are often prescribed for respiratory viral illnes-
ses that will not be covered by antibiotic medica-
tion. Prescribing antibiotics for self-limiting illnesses 
is perhaps the main reason for the emergence of 
antibiotic-resistant bacteria in the community set-
ting [6-8]. It is perplexing to consider the reasons 
physicians, who are typically very highly educated 
individuals, choose to prescribe medications that 
will do more harm than good for the patient and 
society as a whole in the long run. This frightening 
trend has its roots in many factors. Despite their re-
asons, the truth remains that antibiotic prescription 
is not always based on clinical factors alone [5, 8]. 
It has been suggested that antibiotic over-prescri-
bing can be correlated with the prescriber’s indivi-
dual personality and environment. Clinician charac-
teristics that have been linked to unnecessary pres-
cribing include years of practice, medical specialty, 
perceived patient expectations, and desire to please 
the patient [5-6]. General practitioners prescribe so-
mewhere around ninety percent of the antibiotics 
prescribed in the United States for a given year and 
more than half of these are prescribed to treat respi-
ratory tract infections [7]. Statistics are very close to 
these numbers for most highly developed European 
countries as well [13]. Urinary tract infections are the 
second most common disease for which antibiotics 
are typically prescribed. It is estimated that more 
than 50% of patients who present to a primary 
care facility with symptoms of a urinary tract infec-
tion are treated right away with antibiotics, despite 
the fact that urinary tract infections are incredibly 
self-limiting, and pose a very small threat to an 
individual’s overall health and wellbeing [1, 14]. 
Treating urinary tract infections with antibiotics 
before performing the necessary culture and lab 
work is not only irresponsible from a microbial re-
sistance point of view; it is also quite costly and 
ineffective in treating the illness. The patient may be 
given peace of mind knowing that he was prescri-
bed something tangible, but the benefit will go no 
further. The harm done by prescribing antibiotics for 
urinary tractinfections far outweighs the good it will 
do to the patient. The majority of the responsibility 
for the ineffective and irresponsible prescribing of 
antibiotics lies with the prescribers, whether they 
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be physicians, physician assistants, or other medi-
cal faculty [15]. However, the patient also bears a 
portion of the blame and responsibility. It is indeed 
patient expectations and presuppositions that make 
doctors feel bullied or forced into prescribing anti-
biotics either “just in case”, or to please patients 
who will not be satisfied unless they leave with a 
prescription [8].
A study was performed in Iceland to examine 
how often and in what contexts medical practi-
tioners; specifically family and general practitioners 
prescribe antibiotic drugs to patients who present 
with no clear or definite signs of bacterial infec-
tion. Arason calls this prescribing method “non-
pharmacological prescriptions of antibiotics” [6]. 
The study found that the primary reasons doctors 
would prescribe antimicrobial drugs to a patient 
with a non-definite bacterial illness are all related 
to the ever changing doctor-patient relationship. 
In the region studied, the reason for this fluctua-
tion in doctor-patient relations was supposed to 
be the lack of continuity in medical care that most 
patients sought out. Pressure from patients in a 
stressful society, the physician’s heavy work pres-
sure, the prescriber’s own personality, any supple-
mental income or prescribing incentives they may 
be receiving from pharmaceutical companies, and 
the physician’s lack of confidence or uncertainty in 
their diagnostic abilities were the main factors that 
resulted in a situation in which antibiotic prescrip-
tions were prescribed as a kind of coping strategy 
for an uncomfortable situation with a patient [6]. 
A European study surveyed one thousand gene-
ral practitioners about their prescribing habits and 
practices, and 55% of the general practitioners 
admitted to feeling under intense pressure from 
patients to prescribe antibiotics, even if the practi-
tioner insisted and explained to them that the an-
tibiotic was unnecessary and would be ineffective. 
A total of 44% of the general practitioners further 
admitted to prescribing antibiotics to certain pa-
tients just to get them to leave the office [7]. 
The over-prescription of antibiotic drugs is parti-
cularly prevalent among pediatric patients. A study 
in the Scandanavian Journal of Primary Health Care 
found that children under the age of seven consu-
med nearly 20% of the total antibiotic medication 
sold, though they comprised only about 10% of the 
total family care office visits. Over half of these pa-
tients were prescribed antibiotics due to ear infec-
tions, which are rarely caused by bacterial than viral 
infection [6]. A correlation was found between the 
amount of antibiotics an individual child consumed 
and the risk of that patient being a carrier of anti-
biotic resistant microbes, specifically penicillin non-
susceptible pneumococci, in the weeks following 
the medical treatment [6]. 
Pediatric ear infections are some of the most 
common illnesses that prescribers an antibiotic to 
treat [10]. Upper respiratory tract infections are 
the leading cause of antibiotic overprescribing 
in the outpatient setting, both for pediatric and 
adult patients [13]. Another study done in Swe-
den found that after the implementation of more 
thorough diagnostic techniques, fewer patients 
were being diagnosed with bacterial upper res-
piratory infections. Shockingly, the proportion of 
patients who were prescribed an antibiotic did not 
decrease as may be expected. The proportion of 
patients who were prescribed an antibiotic actually 
increased over the time period studied [6]. This 
study shows definitively that clinical factors such 
as bacterial culture workups, are very low on the 
list of reasons a prescriber would prescribe anti-
biotic drugs to a patient. A cause that may be a 
contributor to unnecessary antibiotic prescribing is 
the fact that antibiotic over-prescription has been 
shown to increase the likelihood that patients will 
return to physician office [7]. Knowing that one 
can go into a doctor’s office and leave with defi-
nitive treatment, regardless of whether or not that 
treatment is appropriate for one’s individual case 
and condition, will increase the likelihood of the 
individual bringing their business back to that pro-
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vider. Patient loyalty is likely a contributing factor 
to the antibiotic crisis [7-8].
Role of patients
Patients have become far more demanding for anti-
biotic treatment. They often believe that if they leave 
a doctor’s office without an antibiotic or other tan-
gible and definitive treatment, they are being short 
managed or cheated in some way. Patients consider 
physcians as lazy and uncaring if they choose not 
to prescribe a medication for the individual’s illness 
[14]. Misconceptions and presuppositions are com-
monly present within the public’s belief as it perta-
ins to antibiotics. A study done in Europe looked at 
what the public believes about antibiotics and their 
effectiveness. The study found that about 50% of 
the patients surveyed believed that antibiotics were 
fully effective in treating viruses, cold, and flu and 
should definitely be prescribed in those cases [7]. 
This is alarming, because none of those illnesses will 
be improved by antibiotics. Antibiotics are effective 
only against bacterial infections, not against viruses 
like the ones that can cause ear infections, respira-
tory infections, flu, and the common cold.
Patient characteristics that coincide with exces-
sive and unnecessary antibiotic prescribing include 
misperceptions about antibiotic effectiveness for 
viral illnesses, desire for a tangible product from 
the clinical encounter, age, ethnic consideration and 
insurance status [5, 7]. Older patients from underpri-
vileged areas and minority patients were the groups 
that received unnecessary antibiotics the most. A 
study of Ackerman suggests that it is difficult to 
converse with some patients and explain them un-
pleasant or complicated information about usage 
of antibiotics [5]. These relation do make for a so-
metimes difficult interaction between physician and 
patients. Social characteristics of the doctor-patient 
relationship as mentioned above must definitely be 
considered when looking at the issue of antibiotic 
over-usage [5]. However, the ongoing cultural shift 
in the expected role of the patient from passive 
receiver of medical expertise to active medical “con-
sumer” must also be heavily considered [7]. People 
expect to be sold something and, when they are 
turned away without medication, they feel cheated 
or short treated in some way. 
Role of bacterial culture
The uncertainty involved in diagnostic culture tes-
ting also contributes to overprescribing of antibio-
tics, particularly in the primary care setting. A Dutch 
study done in 2005 showed that the use of antibio-
tics was very strongly linked to physicians wanting 
to avoid uncertainty in diagnosing patients rather 
than actual clinical indications of a bacterial illness 
[8]. Physicians want to eliminate the possibility of 
withholding antibiotic treatment from a patient only 
to have them suddenly develop a serious bacterial 
infection, and become severely ill or even die. The 
legal issues and moral questions weigh heavily on 
the backs of doctors facing these choices. The pro-
blem is that the likelihood of misdiagnosing a life 
threatening bacterial infection as a self-limiting viral 
illness is incredibly small. By providing a “blanket 
coverage” antibiotic prescription just to ease the 
patient’s worries or prevent a second visit for the 
physician. The crisis of antibiotic resistance is being 
further propagated, and it is not beneficial to the 
patient or physician to practice antibiotic prescrip-
tion for just please the patient's desire [8, 11].
Antibiotic resistance in Morocco and 
neighboring countries
Antibiotic resistance is rising to dangerously high 
levels in all parts of the world including Morocco 
and other neighboring African countries, and bac-
teria are becoming alarmingly antibiotic multidrug 
resistant. For example, Staphylococcus aureus is one 
the organism which has developed remarkable high 
level of resistance against multiple antibiotics, and 
complicating treatment. Historically, S. aureus resis-
tance emerged within 2 years of the introduction 
of penicillin [17]. In 1942, the first penicillin-resis-
tant S. aureus strain was detected, the semisynthe-
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tic antibiotic methicillin was then developed in the 
late 1950s developed as a type of a penicillinase-
resistant penicillin, and methicillin-resistant S. au-
reus (MRSA) was clinically first identified in 1960 
[17]. Infections due to MRSA strains are associated 
with higher mortality rates than infections caused 
by methicillin-susceptible strains. In addition, MRSA 
infection is associated with increased lengths of 
hospital stays and high health care costs [17].
Currently, over 95% of S. aureus is resistant to 
not only penicillin, but also ampicillin and the anti-
pseudomonal penicillins [18]. Hospitals are breeding 
grounds for bacterial resistance because they pro-
vide an ideal environment for the development of 
multidrug resistant bacteria by promoting the over-
growth of particular strains of bacteria that carry 
the gene for drug resistance. Clostridium difficile is 
another example of this phenomenon. When an-
tibiotics are used unnecessarily or indiscriminately, 
the normal bacteria that live in the gut can be dis-
rupted and killed, allowing drug-resistant bacteria 
to overgrowth other types of bacteria. C. difficile 
is the most prominent of these bacteria. Antibiotic 
treatment of hospitalized patients causes alterations 
of the intestinal microbial composition, increased C. 
difficile colonization and consecutive toxin produc-
tion leading to disruption of the colonic epithelial 
cells. Clinical symptoms of C. difficile infection ran-
ge from mild diarrhea to potentially life-threatening 
conditions like pseudomembranous colitis or toxic 
megacolon [19]. Extensive antimicrobial treatment 
applies selective pressure on normal body bacteria. 
This pressure favors the emergence of certain strains 
of the bacteria that will be multidrug resistant to 
the various antibiotic classes and therefore able to 
survive in hospital environment and causing often 
nosocomial infections [7-8, 12]. 
A recent study reveals the high incidence of anti-
biotic resistance to three pathogens in five African 
countries Algeria, Egypt, Morocco, Senegal and Tu-
nisia. Antibiotic resistance in these countries has 
reached alarming proportions to Pseudomonas 
aeruginosa including resistance to the two most 
valuable drugs ceftazidime and imipenem (Table 1) 





Algeria Egypt Morocco Senegal Tunisia Total
mg/l n=60 % n=56 % n=120 % n=58 % n=120 % n=414 %
Levofloxacin
S≤1 54 89.8 28 50.0 66 55.1 52 89.7 88 73.3 288 69.6
I 0 0 2 3.6 1 0.8 1 1.7 2 1.7 6 1.5
R>2 6 10.2 26 46.4 53 44.1 5 8.6 30 25.0 120 28.9
Ciprofloxacin
S≤0.5 54 89.8 29 51.8 67 55.9 53 91.4 88 73.3 291 70.1
I 1 1.7 0 0 1 0.8 0 0 4 3.3 6 1.5
R>1 5 8.5 27 48.2 52 43.2 5 8.6 28 23.3 117 28.4
Colistin
S≤4 60 100.0 N/A 120 100.0 58 100.0 120 100.0 358 100.0 87.50
R>4 0 0 N/A 0 0 0 0 0 0 0 0 62.50
Ceftazidime
S≤8 50 83.1 38 68.4 86 72.0 57 98.3 103 85.8 334 80.8
R>8 10 16.9 18 31.6 34 28.0 1 1.7 17 14.2 80 19.2
Imipenem
S≤4 54 89.8 40 71.9 91 75.4 58 100.0 97 80.8 340 82.1
I 1 1.7 7 12.3 3 2.5 0 0 4 3.3 15 3.6
R>8 5 8.5 9 15.8 26 22.0 0 0 19 15.8 59 14.3
Tobramycin
S≤4 60 100.0 35 63.2 83 69.5 54 93.1 100 83.3 332 80.3
R>4 0 0 21 36.8 37 30.5 4 6.9 20 16.7 82 19.7
I: intermediate; N/A: not analyzed; R: resistant; S: susceptible.
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Algeria Egypt Morocco Senegal Total
mg/l n=60 % n=39 % n=101 % n=12 % n=218 %
Penicillin
S≤0.06 34 56.7 20 51.3 86 85.0 11 91.7 152 69.7
I 25 41.7 16 41.0 15 15.0 1 8.3 62 28.4
R>2 1 1.7 3 7.7 0 0 0 0 4 1.8
Amoxicillin
S≤0.5 51 85.0 31 79.5 95 94.0 12 100.0 192 88.0
I 9 15.0 6 15.4 6 6.0 0 0 23 10.6
R>2 0 0 2 5.1 0 0 0 0 3 1.4
Cefotaxime
S≤0.5 57 95.0 29 74.3 98 97.0 12 100.0 202 92.6
I 3 5.0 9 23.1 3 3.0 0 0 15 6.9
R>2 0 0 1 2.6 0 0 0 0 1 0.5
Cefpodoxime
S≤0.25 42 70.0 28 71.8 93 91.8 11 91.7 176 80.9
I 3 5.0 2 5.1 4 4.1 0 0 9 4.2
R>0.5 15 25.0 9 23.1 4 4.1 1 8.3 33 14.9
Erythromycin
S≤0.25 37 61.7 24 61.5 86 85.1 12 100.0 159 72.9
I 0 0 0 0 0 0 0 0 1 0.5
R>0.5 23 38.3 15 38.5 15 14.9 0 0 58 26.6
PNSP + erythromycin R 18 30.0 11 28.2 4 3.9 0 0 37 16.9
I: intermediate; PNSP: penicillin non-susceptible pneumococci; R: resistant; S: susceptible.






Algeria Egypt Morocco Senegal Tunisia Total




Methicillin R 33 45.8 37 62.7 13 11.3 3 5.0 22 18.0 108 25.2
MIC Etest
Teicoplanin S≤2 mg/l 72 100.0 45 76.3 108 93.9 60 100.0 118 96.7 403 94.2
Teicoplanin R>2 mg/l 0 0 14 23.7 7 6.1 0 0 4 3.3 25 5.8
MIC Etest
Levofloxacin S≤1 mg/l 64 88.9 51 86.4 107 93.0 60 100.0 111 91.0 393 91.8
Levofloxacin I 6 8.3 1 1.7 1 0.9 0 0 1 0.8 9 2.1
Levofloxacin R>2 mg/l 2 2.8 7 11.9 7 6.1 0 0 10 8.2 26 6.1
Disc Fosfomycin S 72 100.0 59 100.0 115 100.0 60 100.0 119 97.5 425 99.3
Disc Erythromycin S 54 75.0 23 39.0 102 88.7 57 95.0 99 81.1 335 78.3
Disc Gentamicin S 62 86.2 17 29.2 110 95.7 60 100.0 117 95.9 366 85.5
Disc Pristinamycin S 67 93.1 40 67.8 114 99.1 60 100.0 122 100.0 403 94.2
I: intermediate; MIC: minimal inhibitory concentration; R: resistant; S: susceptible.
[20]. In addition, the study documented high ra-
tes of Streptococcus pneumonia penicillin-resistant 
in Algeria, Egypt, Morocco and Senegal (Table 2), 
and methicillin-resistant S. aureus (MRSA) in Alge-
ria and Egypt, Morocco, Senegal and Tunisia with 
the emergence of Staphylococcus strains interme-
diate resistant to teicoplanin. (Table 3). There are 
also numerous recent studies from Algeria, Moroc-
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co, Libya and Tunis which have reported the wide 
spread of multidrug resistance and extended-spec-
trum β-lactamases genes among Gram-negative 
bacteria such as Enterobacteriaceae, particularly 
among E. coli and Klebsiella pneumoniae isolates 
from patients [21-28]. These findings are alarming 
and should encourage to implement urgently the 
recommendations of the WHO to employ regular 
monitoring and surveillance of bacterial resistance 
to antibiotics in these countries [3]. In addition, 
a new study from Morocco has reported on the 
emergence of carbapenemases genes, such as 
blaOXA-24, blaOXA-23, blaOXA-58 and blaNDM in 
A. baumannii isolates from three hospitals [29]. 
Another study also reported by Uwingabiye on 
the production of carbapenemase in A. bauman-
nii isolates, collected from different patients and 
different places of a Moroccan hospital [30]. The 
emergence and spread of carbapenemase-produ-
cing carbapenem-resistant bacteria is a significant 
clinical and public health concern since it is asso-
ciated with high mortality [31]. 
Dangerous consequence of bacterial 
resistance 
What is of most concern is that common bacterial 
infections such as streptococcal throat may once 
again become untreatable due to develop of bac-
terial resistance. The WHO has outlined what a 
possible future could look like if antibiotic resistan-
ce grows with higher speed. They have named it 
the “post-antibiotic world”. This world looks a lot 
less like Pasteur’s hope of the future destruction 
of disease and much more like the pre-penicillin 
era when infectious disease dominated. The WHO 
warns that antibiotic resistance may soon result in 
simple infections becoming unmanageable and po-
tentially even fatal [1, 3]. 
Potential solutions 
Several approaches have been suggested by scien-
tists, physicians, and other professionals for the con-
trol of further drug resistance development. These 
include educating the public about the proper use of 
antibiotics and the consequences of misusing them, 
holding physicians and health care professionals to 
a much higher standard when it comes to diag-
nosing and treating patients with bacterial illness. 
Additionally, appling stricter regulations for when 
antibiotics can and should be prescribed, and incre-
asing the search for discovering of new antibiotics. 
Multifaceted interventions that attack the problem 
from several sides will be the most effective ap-
proach in fighting back against antibiotic resistance. 
The interventions that have shown the best results 
in countries worldwide include: the enforcement of 
policies prohibiting the sale and purchase of anti-
biotics without a valid prescription from a qualified 
dispensing physician or certain cases of pharmacist. 
Second, the use of stewardship programs explaining 
the importance of the proper use of antibiotics to 
the public, the enforcement of laboratory culture 
testing before prescribing antibiotics, teaching phy-
sicians how to better manage patient treatment, 
and putting incentives in place for physicians who 
adhere to these guidelines and regulations [7, 14]. 
These steps, among others, are probably necessary 
to slow the development of antibiotic resistance. 
However, we must know that antibiotic resistance 
once established its not easily to reverse over a short 
time [8]. 
Public antibiotic education
The public is seriously misinformed about when an 
antibiotic is necessary and when it is not. There is a 
clear need for general education about the dange-
rous usage of antibiotics without prescription [15]. 
It has been recommended to including material 
about antibiotics and their safe usage into public 
school curriculum plans. This approach could go a 
long way to educate the general public about the 
dangerous use of antibiotic without medical neces-
sity. Informative pamphlets could be given out in 
government buildings such as the Social Security 
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Office. Television could be particularly useful in this 
aspect. Documentaries and news stories could go 
a long way towards educating the public. Social 
media could also potentially be used as a platform 
in spreading the news about antibiotic resistance. 
Public intervention could include the publication 
of guidelines, freely offered educational sessions 
covering what illnesses antibiotics will and will 
not work for, the publication of local interviews 
with pharmacists, messages on radio, television, 
and other mass media platforms [7]. These public 
campaigns will have a positive effect on reducing 
the antibiotic crisis, but educating the public will 
by no means solve the entire antibiotic resistance 
problem [8].
Physician programs and interventions
Since bacterial infection is mostly difficult to dis-
tinguish from viral infection in respiratory tract, 
physicians and providers must be encouraged and 
even required to run rapid diagnostic tests before 
prescribing antibiotics to a patient [15]. This pro-
cedure will often help to show patients about the 
reason they are not being prescribed an antibio-
tic. The patients could be much less likely to put 
pressure on a provider to prescribe antimicrobials 
in situations in which they are not indicated or 
warranted. Culture tests are generally easily to be 
collected in form of a swab, blood or urine sample 
and sending it to the laboratory. Diagnostic testing 
may take a little longer and seem like an incon-
venience to the patient, but the time lost from 
their day will pale in comparison to the impending 
antibiotic crisis if these measures are not taken. 
This is not meant to trivialize a patient’s concerns, 
but to help them understand how antibiotics can 
and should be properly used for the beneficial of 
their health and the society as a whole. Obviously, 
cases such as blood sepsis and meningitis should 
be immediately treated with antibiotics after ta-
king the necessary clinical samples for diagnostic 
testing [8]. 
It is highly important to educate and train physi-
cians about proper using of antibiotics as part of a 
physician’s medical education. It is important that 
physician knows how to select the correct type of 
antibiotics, and knows how to explain to a patient 
with no medical background about use of antibio-
tics. Once the patient is understanding that antibio-
tics will not reduce the duration of viral diseases, 
and that may be only contributing to the antibiotic 
resistance. The information given verbally by the 
provider could be backed up by informational lea-
flets or pamphlets that the patient can take home 
[5, 8]. It is also important that doctors can set realis-
tic expectations for patients about the duration and 
severity of the illnesses they are experiencing. Four 
days is a common running time duration for ear 
infections, about a week for an acute sore throat 
or common cold caused by a virus, two and a half 
weeks for a sinus infection, and up to three weeks 
for a severe cough or bronchitis [7]. This is of parti-
cular importance because studies have shown that 
many patients believe that if they suffer symptoms 
for more than three days, antibiotics are not only 
warranted but absolutely necessary [32-33].
Regulations
The antibiotics currently in use have great impact 
on human life, therefore they must be conserved 
and protected while the search continues for newer 
antibiotics [15]. The ultimate goal of applying re-
gulations to proper usage of antibiotics is not sim-
ply as well as to reduce the number of antibiotics 
being prescribed and utilized. It is highly important 
to encourage the rational use of antibiotics and to 
ensure that they are only being prescribed to pa-
tients who need the treatment and will definitely 
benefit from it [7]. 
The Centers for Disease Control(CDC) in USA, 
has actually already presented a rational program 
to proper use of antibiotics. It is a quite aggressive 
plan aimed at reducing the unnecessary use of 
antimicrobials, so that antibiotics remain a viable 
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tool for future generations [34]. In fiscal year 2016, 
USA congress allocated nearly $160 million for the 
CDC to support different agencies and programs 
in the fight against antimicrobial resistance. With 
these investments, CDC implemented the Anti-
biotic Resistance Solutions Initiative, which is im-
proving national infrastructure to detect, respond, 
and contain resistant infections across healthcare 
settings and communities. This plan does have its 
flaws. It is aimed primarily at hospital use of anti-
biotics, not towards general practitioners of family 
practitioners. Also, the CDC’s proposed plan does 
not address the use of antibiotics in agriculture 
and livestock. The CDC includes several categories 
of goals in the fight against antibiotic resistance. 
They hope to set national goals to improve antibio-
tic use, particularly to cut inappropriate prescribing 
practices by fifty percent in hospitals and twenty 
percent in the general practitioner and specialists’ 
offices. They plan to encourage effective public 
information and antibiotic stewardship programs, 
focusing their efforts on doctors’ offices, hospitals, 
and nursing homes. The CDC has provided fun-
ding to researchers who are studying antimicrobial 
resistance, and those who are searching for new 
antimicrobial substances that could potentially be 
used in the treatment of patients. Interestingly, 
they also have begun a program in support of the 
early recognition of sepsis [32]. All of these initia-
tives sound very noble and promising. However, 
the CDC has yet to set forth a practical approach 
to fighting antimicrobial resistance. All of their 
planning thus far has been focused toward future 
initiatives, not at present time. Unfortunately, the 
antibiotic crisis is happening today, not in the dis-
tant future.
Pharmaceutical companies must be prevented 
from offering prescribing incentives to medical 
providers, potentially through legal action. This is 
probably one of the toughest issues to be overco-
me. It may be impossible to prevent pharmaceuti-
cal companies to offer free samples of antibiotics 
for physicians. For the time being, the role of “Big 
pharma” must be recognized and possibly coun-
tered by public pressure and governmental regu-
lations. 
Antibiotics for use in animals should be admi-
nistered only by a licensed veterinarian, directly or 
through writing a prescription that a pharmacy can 
fill [15]. Antibiotics should by no means be sprayed 
onto crops or included in the food of livestock as 
a preventative measure. The link between animal 
health and human health must be clearly recogni-
zed and integrated into the plans taken by health 
professionals, regulatory agencies, and the enfor-
cing authorities [12].
Search for new antibiotics
The search for new antibiotics is well underway, 
though it is moving at an alarmingly slow rate. It is 
much more difficult for researchers to find financial 
support from pharmaceutical companies to search 
for and develop new drugs. The time delay between 
the discovery of a potential new antimicrobial subs-
tance and the approval to commercially produce it 
is on the magnitude of decades [15]. This has led 
many researchers to abandon the search for new 
antibiotics entirely, as there is not enough interest 
or funding.
Conclusions
In Morocco and neighboring countries the problem 
of antibiotic resistance is recognized and well do-
cumented by presence of numerous published stu-
dies during recent years as shown in this review. 
Rapidly emerging resistant bacteria threaten the 
extraordinary health benefits that have been achie-
ved until now with antibiotics. The antibiotic crisis 
is global, reflecting the worldwide overuse of these 
drugs and the lack of development of new antibio-
tic agents by pharmaceutical companies. Antibiotic-
resistant infections place a substantial health and 
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economic burden on the health care system and 
population. Coordinated efforts of all health pro-
fessionals worldwide with the support of govern-
mental regulations are needed to implement new 
policies, renew research efforts, and pursue steps 
to manage the antibiotic crisis are greatly needed.
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